Hypophosphatasia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Hypophosphatasia (HPP) arises from a genetic anomaly affecting the gene responsible for encoding tissue-nonspecific isozyme of alkaline phosphatase (TNAP), resulting in a loss-of-function mutation(s). The disease presents across various stages of life, classified into perinatal, infantile, childhood, and adult HPP, along with odonto HPP and perinatal benign forms. Perinatal/immature HPP often proves fatal, characterized by severe rickets, respiratory insufficiency, hypercalcemia, and sometimes vitamin B6-responsive seizures in affected infants. The principal biochemical deficiency in HPP involves reduced TNAP activity, leading to elevated levels of substrates, particularly inorganic pyrophosphate (PPi), a potent calcification inhibitor. The clinical severity varies widely. Strensiq (asfotase alfa), an FDA-approved medication, addresses hypophosphatasia (HPP) in children. Initially sanctioned in 2015, it targets childhood-onset, juvenile-onset, and perinatal HPP. Strensiq, a recombinant TNSALP enzyme replacement therapy, enhances survival and ameliorates severe musculoskeletal deficits, metabolic disruptions, and functional limitations associated with more severe HPP forms.
• Hypophosphatasia (HPP) is a rare heritable condition, with an incidence of 1 in 100,000 individuals.

Thelansis’s “Hypophosphatasia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypophosphatasia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Hypophosphatasia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Hypophosphatasia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Hypophosphatasia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033